U.S. Food and Drug Administration (FDA) last week approved the Psoriatic Arthritis (PsA) treatment, ORENCIA (abatacept) by Bristol-Myers Squibb Company.
ORENCIA is approved and available in both intravenous and subcutaneous (SC) injection formulations for the treatment of adults with active PsA.
This approval marks the third autoimmune disease indication for ORENCIA.
“This approval underscores the efficacy of ORENCIA in adult patients with active Psoriatic Arthritis, who have been in need of new treatments,” said Brian J. Gavin, Vice President, ORENCIA Development Lead at Bristol-Myers Squibb. “Helping to advance clinical understanding of autoimmune conditions is a key focus of our immunoscience research, and we’re proud to introduce ORENCIA, a selective T-cell co-stimulation modulator, as an additional treatment option for PsA.”
The co-stimulation blockade of ORENCIA inhibits T-cell activation and the resulting cascade of events that contribute to inflammation. T-cell activation is involved in the pathogenesis of PsA.
Psoriatic Arthritis can cause joint pain, stiffness and reduced range of motion, potentially affecting the ability to do everyday activities, such as getting dressed and tying shoes. In PsA, the immune system attacks healthy joints and skin.
“Psoriatic Arthritis takes a toll on patients and families over time,” said Randy Beranek, president and CEO, National Psoriasis Foundation. “We welcome the introduction of an additional treatment option for adults with active Psoriatic Arthritis, because we believe advancements, along with further research, education and support services, are critical to helping improve the lives of those impacted.”
ORENCIA should not be administered concomitantly with TNF antagonists, and is not recommended for use concomitantly with other biologic Rheumatoid Arthritis (RA) therapy, such as anakinra.
- Psoriasis: Oral treatment clinical trials
- July is International Group B Strep Awareness Month
- Vaccines: How they work and some common misconceptions
- Legionnaires’ disease and Legionella, Part Two
- The ABCs of melanoma